January 4th, 2012
•Type B gelatin-based engineered nanovectors system (GENS) was developed for systemic gene delivery and transfection in the treatment of pancreatic cancer. By modification with epidermal growth factor receptor (EGFR) specific peptide on the surface of nanparticles, they could target on EGFR receptor and release plasmid under reducing environment, such as high intracellular glutathione concentrations.
Tags
Vídeos Relacionados
Evaluation of Polymeric Gene Delivery Nanoparticles by Nanoparticle Tracking Analysis and High-throughput Flow Cytometry
Transplantation of Induced Pluripotent Stem Cell-derived Mesoangioblast-like Myogenic Progenitors in Mouse Models of Muscle Regeneration
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Electrospinning Growth Factor Releasing Microspheres into Fibrous Scaffolds
Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
Designing Porous Silicon Films as Carriers of Nerve Growth Factor
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados